Sai Life Sciences Limited has informed the Exchange regarding Appointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO of the company w.e.f. September 01, 2025.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences' board has approved the reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for a five-year term from September 1, 2025 to August 31, 2030, pending shareholder approval at the upcoming AGM. Mr. Kanumuri has been with the company since 2004 and currently leads it — he spearheaded the December 2024 IPO, set up R&D centres in Boston and Manchester, and drove a 25% revenue CAGR between 2022 and 2025. He is the son of Dr. K Ranga Raju, the company's Chairman and Promoter. The reappointment is subject to shareholder approval at the AGM and he is not debarred by any regulatory authority.
This is a continuity move with no leadership change, generally viewed positively as it signals board confidence in the existing growth strategy. Shareholders should note the reappointment still requires their approval at the AGM, and the promoter-family linkage may attract governance attention from some investors.